English 
Español
Development and validation of a mass spectrometric method to determine the identity of rituximab based on its microheterogeneity profile. IN PRESS
Related Articles
-
UDIBI
Published: april 10, 2019 CD80 Expression Correlates with IL-6 Production in THP-1-Like Macrophages Costimulated with LPS and Dialyzable Leukocyte...
-
UDIBI
Colloids and Surfaces A: Physicochemical and Engineering Aspects. Structural and physicochemical characteristics of one-step PAMAM dendrimeric nanoparticles. SHOW MORE
-
UDIBI
Published: may 16, 2019 Development of Functional Antibodies Directed to Human Dialyzable Leukocyte Extract Transferon®) More information
-
UDIBI
Published: april 2nd, 2020 Development and Evaluation of a Set of Spike and Receptor Binding Domain‐Based Enzyme‐Linked Immunosorbent Assays...
-
-
UDIBI
Isolation and characterization of high affinity and highly stable anti-Chikungunya virus antibodies using ALTHEA Gold Libraries™. SHOW MORE
-
UDIBI
Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc región....
-
UDIBI
Sequencing Analysis and Identification of the Primary Peptide Component of the Dialyzable Leukocyte Extract “Transferon Oral”: The Starting Point...
